Candriam S.C.A. Crinetics Pharmaceuticals, Inc. Transaction History
Candriam S.C.A.
- $15.6 Billion
- Q1 2025
A detailed history of Candriam S.C.A. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 488,911 shares of CRNX stock, worth $15.8 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
488,911Holding current value
$15.8 Million% of portfolio
0.11%Shares
3 transactions
Others Institutions Holding CRNX
# of Institutions
235Shares Held
87MCall Options Held
40KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA9.31MShares$301 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$223 Million0.05% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.24MShares$202 Million2.28% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$201 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.11MShares$165 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.74B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...